Paul Choi
Stock Analyst at Goldman Sachs
(3.90)
# 640
Out of 4,981 analysts
107
Total ratings
53.62%
Success rate
10.31%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $15.01 | -20.05% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $18.79 | -84.03% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $3.46 | +131.21% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $11.84 | -57.77% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $7.74 | +3.36% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $36.20 | +43.67% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.00 | +320.00% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $9.20 | +30.43% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $2.84 | +5.63% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $9.41 | +6.27% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $195.58 | +15.04% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $52.94 | +170.12% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $61.11 | -31.27% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $51.13 | +17.35% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $17.93 | +5.97% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $37.10 | -13.75% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $51.21 | -2.36% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.19 | +266.09% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $12.03 | +315.63% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.23 | +1,932.52% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $13.93 | +1,120.39% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $4.47 | +78.97% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $141.90 | -4.86% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $48.68 | +516.27% | 2 | Mar 30, 2020 |
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $15.01
Upside: -20.05%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $18.79
Upside: -84.03%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.46
Upside: +131.21%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.84
Upside: -57.77%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $7.74
Upside: +3.36%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $36.20
Upside: +43.67%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.00
Upside: +320.00%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $9.20
Upside: +30.43%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.84
Upside: +5.63%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $9.41
Upside: +6.27%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $195.58
Upside: +15.04%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $52.94
Upside: +170.12%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $61.11
Upside: -31.27%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $51.13
Upside: +17.35%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $17.93
Upside: +5.97%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $37.10
Upside: -13.75%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $51.21
Upside: -2.36%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.19
Upside: +266.09%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $12.03
Upside: +315.63%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.23
Upside: +1,932.52%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $13.93
Upside: +1,120.39%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $4.47
Upside: +78.97%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $141.90
Upside: -4.86%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $48.68
Upside: +516.27%